Latest Insider Transactions at Catalyst Pharmaceuticals, Inc. (CPRX)
This section provides a real-time view of insider transactions for Catalyst Pharmaceuticals, Inc. (CPRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CATALYST PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CATALYST PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 14
2022
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
143,000
+43.04%
|
$572,000
$4.33 P/Share
|
Sep 14
2022
|
Alicia Grande VP, Treasurer and CFO |
SELL
Open market or private sale
|
Direct |
50,000
-12.27%
|
$750,000
$15.57 P/Share
|
Sep 14
2022
|
Donald A Denkhaus Director |
SELL
Open market or private sale
|
Direct |
20,000
-6.3%
|
$300,000
$15.34 P/Share
|
Sep 14
2022
|
Philip H Coelho Director |
SELL
Open market or private sale
|
Direct |
20,000
-7.42%
|
$300,000
$15.75 P/Share
|
Sep 14
2022
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
946,846
-19.52%
|
$14,202,690
$15.41 P/Share
|
Sep 13
2022
|
Philip H Coelho Director |
SELL
Open market or private sale
|
Direct |
10,000
-3.58%
|
$150,000
$15.7 P/Share
|
Sep 13
2022
|
Steve Miller Chief Op. & Scientific Officer |
SELL
Open market or private sale
|
Direct |
107,933
-4.88%
|
$1,726,928
$16.99 P/Share
|
Sep 13
2022
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
80,765
-1.64%
|
$1,211,475
$15.33 P/Share
|
Aug 29
2022
|
Alicia Grande VP, Treasurer and CFO |
SELL
Open market or private sale
|
Direct |
57,000
-4.27%
|
$798,000
$14.21 P/Share
|
Aug 26
2022
|
Alicia Grande VP, Treasurer and CFO |
SELL
Open market or private sale
|
Direct |
11,095
-2.33%
|
$155,330
$14.4 P/Share
|
Aug 24
2022
|
Richard J Daly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+30.15%
|
$80,000
$2.53 P/Share
|
Aug 22
2022
|
David S Tierney Director |
SELL
Open market or private sale
|
Direct |
20,000
-6.09%
|
$280,000
$14.16 P/Share
|
Aug 22
2022
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+5.74%
|
$40,000
$2.53 P/Share
|
Aug 19
2022
|
Jeffrey Del Carmen Chief Commercial Officer |
BUY
Open market or private sale
|
Direct |
14,140
+100.0%
|
$197,960
$14.05 P/Share
|
Aug 19
2022
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
125,000
-2.47%
|
$1,750,000
$14.1 P/Share
|
Aug 19
2022
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+2.41%
|
$250,000
$2.53 P/Share
|
Aug 18
2022
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
175,000
-0.88%
|
$2,275,000
$13.94 P/Share
|
Aug 18
2022
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+0.99%
|
$100,000
$2.53 P/Share
|
Aug 18
2022
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+0.83%
|
$250,000
$2.53 P/Share
|
Aug 18
2022
|
Steve Miller Chief Op. & Scientific Officer |
SELL
Open market or private sale
|
Direct |
150,000
-8.72%
|
$1,950,000
$13.5 P/Share
|
Aug 18
2022
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+7.84%
|
$300,000
$2.53 P/Share
|
Aug 18
2022
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+5.77%
|
$80,000
$2.53 P/Share
|
Aug 18
2022
|
Alicia Grande VP, Treasurer and CFO |
SELL
Open market or private sale
|
Direct |
19,259
-3.89%
|
$250,367
$13.7 P/Share
|
Aug 18
2022
|
Alicia Grande VP, Treasurer and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,259
+3.75%
|
$38,518
$2.53 P/Share
|
Aug 17
2022
|
Philip H Coelho Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+12.52%
|
$80,000
$2.53 P/Share
|
Aug 17
2022
|
Alicia Grande VP, Treasurer and CFO |
SELL
Open market or private sale
|
Direct |
130,741
-11.74%
|
$1,699,633
$13.86 P/Share
|
Aug 17
2022
|
Alicia Grande VP, Treasurer and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
130,741
+10.28%
|
$261,482
$2.53 P/Share
|
Jun 28
2022
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,930
-17.16%
|
-
|
Jun 28
2022
|
Jeffrey Del Carmen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+36.94%
|
-
|
Jun 22
2022
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
6,152
-21.81%
|
$36,912
$6.61 P/Share
|
Jun 22
2022
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,152
+17.91%
|
$24,608
$4.13 P/Share
|
Jun 21
2022
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
143,848
-86.71%
|
$863,088
$6.59 P/Share
|
Jun 21
2022
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
143,848
+46.44%
|
$575,392
$4.13 P/Share
|
May 20
2022
|
David S Tierney Director |
SELL
Open market or private sale
|
Direct |
20,000
-6.09%
|
-
|
May 20
2022
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+5.74%
|
$40,000
$2.53 P/Share
|
Jan 25
2022
|
Richard J Daly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+48.7%
|
$150,000
$3.35 P/Share
|
Jan 10
2022
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+11.18%
|
$80,000
$2.53 P/Share
|
Jan 05
2022
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+15.26%
|
$150,000
$3.35 P/Share
|
Dec 07
2021
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
3,612
-14.07%
|
$21,672
$6.99 P/Share
|
Dec 07
2021
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,667
+36.37%
|
-
|
Dec 03
2021
|
Philip H Coelho Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+0.55%
|
-
|
Dec 03
2021
|
Richard J Daly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+33.33%
|
-
|
Dec 03
2021
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+0.58%
|
-
|
Dec 03
2021
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+0.22%
|
-
|
Dec 03
2021
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+0.43%
|
-
|
Dec 03
2021
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+2.56%
|
-
|
Dec 03
2021
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,571
-12.17%
|
-
|
Dec 03
2021
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,667
+33.33%
|
-
|
Dec 03
2021
|
Alicia Grande VP, Treasurer and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,571
-0.75%
|
-
|
Dec 03
2021
|
Alicia Grande VP, Treasurer and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,667
+2.97%
|
-
|